Share

Treatment optimisation: making cancer treatment accessible and sustainable in Europe (lunch meeting)

Brussels, Belgium (hybrid)

The oncology academic community is sounding the alarm on the overuse of anti-cancer drugs. Optimal doses, treatment durations, sequences, and combinations of new anti-cancer drugs are often not identified at the time of marketing authorisation. Therefore, patients are experiencing unnecessary side effects and healthcare budgets are pressured by avoidable costs.

To address this situation, independent clinical research beyond market access must be facilitated. The role of the academic sector is needed to generate independent evidence that will guide clinicians to the optimal use of anti-cancer drugs. Treatment optimisation clinical trials, such as those focusing on treatment de-escalation, are key.

This event organised by EORTC and hosted by Mrs Tilly Metz (Greens), co-hosted by Mrs Romana Jerkovic (S&D) at the European Parliament will bring together various stakeholders to discuss the challenges and solutions for optimising cancer treatment in Europe.

In-person registration is now closed. Online participation remains open until 23 September 2025.

This is a hybrid event, lunch will be served to in-person participants. Please note that in-person participation will be subject to confirmation by 12 September 2025 because of the limited capacity of the venue. There is no restriction to online participation.

Speakers

Agenda

Treatment optimisation: making cancer treatment accessible and sustainable in Europe 

12:00-14:00, 24 September 2025, European Parliament, Brussels, Belgium

Time Topic and speaker
12:00 Welcome and introduction “Better use of therapies for efficient and sustainable care in Europe” (T. Metz, MEP)
12:05 Why treatment optimisation is important for European citizens? (R Jerkovic, MEP)
12:10 Setting the scene “What is treatment optimisation and why do we need it?” (D. Lacombe, EORTC)
12:20 Panel discussion “Are we using therapies optimally in Europe?”
Moderator: Y. Natsis (ESIP)

  • Treatment optimisation and the impact on Patients Quality of Life (W. van der Graaf, NKI)
  • Treatment efficiency and patient access (B. Wieseler, IQWIG)
  • Why does it matter for patients and what we all can do to improve the situation? (A. Cardone, CPE)
13:05 Panel discussion “What are the possible solutions?”
Moderator: F. Hulstaert (KCE)

  • The EVOLVE study, the way forward? (M. van der Heijden, NKI)
  • Net trial costs and expected return on investment (Z. Kalo, Syreon)
  • The payer’s perspective (S. Koole, Zilverenkruis)
13:50 Wrap up and conclusion (T. Metz,  MEP, D. Lacombe, EORTC)
14:00 End
Socialists & Democrats

Next events

  • Clinical Trial Statistics for Non-Statisticians 26

    Brussels, BE

  • EORTC Leukemia Spring Group Meeting 2026

    Stockholm, SE

  • EORTC Gynecological Cancer Group Spring Meeting 2026

    EORTC HQ, Brussels, Belgium

  • 26th Workshop on Methods in Clinical Cancer Research (MCCR)

    Sint Michielsgestel, Netherlands

  • EORTC Pathobiology Autumn Group Meeting 2026

    Gmunden, Austria